Skip to content
Trial Eligibility
Menu

CRF2 Agonist for the Treatment of Worsening Heart Failure

NCT06815471

This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .

Summary

This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Worsening Heart Failure

Eligibility basics and study details

Study type
Interventional
Phase
Phase 2
Ages
18 to 85 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
Corteria Pharmaceuticals
Last updated on ClinicalTrials.gov
November 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

North Carolina · 1

  • NC Heart and Vascular Research, LLC · Raleigh, NC

Ohio · 1

  • Ohio State University · Columbus, OH

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.